irinotecan has been researched along with Dermatoses in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, M; Fujikawa, K; Fukai, Y; Hashishita, H; Sagawa, T; Tahatsu, K; Takada, S; Takahashi, Y | 1 |
| Banzi, C; Biasco, G; Bonetti, F; Boni, C; Brandes, A; Calandri, C; Carandina, I; Cataldo, S; DI Fabio, F; Lelli, G; Marzola, M; Nanni, O; Negri, F; Panetta, A; Pantaleo, MA; Ravaioli, E; Turci, D; Urbini, B | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M | 1 |
| Abdel-Aziz, H; Abdelwahab, S; Azmy, A; Mahmoud, A; Salim, H | 1 |
| Amado, RG; Berlin, J; Hecht, JR; Malik, I; Meropol, NJ; Navale, L; Patnaik, A; Tchekmedyian, S; Venook, A | 1 |
| Caliendo, V; Ciorba, A; Ciuffreda, L; Clerico, M; Evangelista, W; Facilissimo, I; Fanchini, L; Macripò, G; Milanesi, E; Paris, M; Racca, P; Ritorto, G; Volpatto, R | 1 |
| Kano, E; Kawahara, K; Ueda, K | 1 |
5 trial(s) available for irinotecan and Dermatoses
| Article | Year |
|---|---|
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Polymerase Chain Reaction; Premedication; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Skin Diseases; Survival Rate; Young Adult | 2011 |
Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Rectal Neoplasms; Skin Diseases; Treatment Outcome | 2012 |
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Skin Diseases; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.
Topics: Anti-Infective Agents, Local; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Skin Diseases | 2008 |
3 other study(ies) available for irinotecan and Dermatoses
| Article | Year |
|---|---|
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Oxaliplatin; Prognosis; Skin Diseases; Survival Rate | 2018 |
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Skin; Skin Diseases; Weight Loss | 2008 |
Effect of peplomycin or camptothecin-11 on X-ray skin injuries of ICR hairless mice.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Irinotecan; Male; Mice; Mice, Hairless; Mice, Inbred ICR; Peplomycin; Radiation Dosage; Radiation Injuries, Experimental; Radiation-Sensitizing Agents; Skin; Skin Diseases; Thigh; Topoisomerase I Inhibitors; X-Rays | 1994 |